121 related articles for article (PubMed ID: 35950848)
41. Tolerability and efficacy of durvalumab, either as monotherapy or in combination with tremelimumab, in patients from Asia with advanced biliary tract, esophageal, or head-and-neck cancer.
Doki Y; Ueno M; Hsu CH; Oh DY; Park K; Yamamoto N; Ioka T; Hara H; Hayama M; Nii M; Komuro K; Sugimoto M; Tahara M
Cancer Med; 2022 Jul; 11(13):2550-2560. PubMed ID: 35611499
[TBL] [Abstract][Full Text] [Related]
42. [A meta-analysis of platinum plus docetaxel or vinorelbine in the first-line treatment of advanced non-small cell lung cancer].
Liu T; Wu H; Zhuang X; Lu D; Cai R; Wang W
Zhongguo Fei Ai Za Zhi; 2014 Apr; 17(4):327-35. PubMed ID: 24758908
[TBL] [Abstract][Full Text] [Related]
43. Platinum-Fluoropyrimidine and Paclitaxel-Based Chemotherapy in the Treatment of Advanced Anal Cancer Patients.
Sclafani F; Morano F; Cunningham D; Baratelli C; Kalaitzaki E; Watkins D; Starling N; Chau I; Rao S
Oncologist; 2017 Apr; 22(4):402-408. PubMed ID: 28209745
[TBL] [Abstract][Full Text] [Related]
44. S-1 Monotherapy After Failure of Platinum Plus 5-Fluorouracil Chemotherapy in Recurrent or Metastatic Esophageal Carcinoma.
Ito T; Honma Y; Hirano H; Shoji H; Okita N; Iwasa S; Takashima A; Kato K; Boku N
Anticancer Res; 2019 Jul; 39(7):3931-3936. PubMed ID: 31262923
[TBL] [Abstract][Full Text] [Related]
45. Salvage systemic therapy for advanced gastric and oesophago-gastric junction adenocarcinoma.
Tomita Y; Moldovan M; Chang Lee R; Hsieh AH; Townsend A; Price T
Cochrane Database Syst Rev; 2020 Nov; 11(11):CD012078. PubMed ID: 33210731
[TBL] [Abstract][Full Text] [Related]
46. Tislelizumab Plus Chemotherapy Sequential Neoadjuvant Therapy for Non-cCR Patients After Neoadjuvant Chemoradiotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma (ETNT): An Exploratory Study.
He W; Wang C; Wu L; Wan G; Li B; Han Y; Li H; Leng X; Du K; Chen H; Wang Q; Peng L
Front Immunol; 2022; 13():853922. PubMed ID: 35720312
[TBL] [Abstract][Full Text] [Related]
47. Polymorphism of
Yang Y; Jia J; Sun Z; Liu C; Li Z; Xiao Y; Yu J; Du F; Shi Y; Sun J; Shui J; Zhang X
Future Oncol; 2021 Jun; 17(18):2351-2363. PubMed ID: 33709789
[TBL] [Abstract][Full Text] [Related]
48. Randomized phase II study of docetaxel versus paclitaxel in patients with esophageal squamous cell carcinoma refractory to fluoropyrimidine- and platinum-based chemotherapy: OGSG1201.
Yamamoto S; Kawakami H; Kii T; Hara H; Kawabata R; Kawada J; Takeno A; Matsuyama J; Ueda S; Okita Y; Endo S; Kimura Y; Yanagihara K; Okuno T; Kurokawa Y; Shimokawa T; Satoh T
Eur J Cancer; 2021 Sep; 154():307-315. PubMed ID: 34311300
[TBL] [Abstract][Full Text] [Related]
49. Approach to Localized Squamous Cell Cancer of the Esophagus.
Weidenbaum C; Gibson MK
Curr Treat Options Oncol; 2022 Oct; 23(10):1370-1387. PubMed ID: 36042147
[TBL] [Abstract][Full Text] [Related]
50. Impact of sequential lines of palliative chemotherapy in patients with recurrent/metastatic esophageal squamous cell carcinoma: A retrospective analysis of 107 patients at a single center.
Kim EJ; Kim JH; Song HJ; Park SR; Kim YH; Kim HR; Kim SB
Asia Pac J Clin Oncol; 2020 Apr; 16(2):e53-e62. PubMed ID: 31657877
[TBL] [Abstract][Full Text] [Related]
51. PRODIGE 59-DURIGAST trial: A randomised phase II study evaluating FOLFIRI + Durvalumab ± Tremelimumab in second-line of patients with advanced gastric cancer.
Evrard C; Louvet C; Hajbi FE; Fiore FD; Malicot KL; Aparicio T; Bouché O; Laurent-Puig P; Bibeau F; Lecomte T; Lièvre A; Guimbaud R; Kim S; Zaanan A; Sokol H; Chibaudel B; Desrame J; Pierre S; Gonzalez D; Lepage C; Tougeron D
Dig Liver Dis; 2021 Apr; 53(4):420-426. PubMed ID: 33358124
[TBL] [Abstract][Full Text] [Related]
52. Sintilimab versus placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic oesophageal squamous cell carcinoma (ORIENT-15): multicentre, randomised, double blind, phase 3 trial.
Lu Z; Wang J; Shu Y; Liu L; Kong L; Yang L; Wang B; Sun G; Ji Y; Cao G; Liu H; Cui T; Li N; Qiu W; Li G; Hou X; Luo H; Xue L; Zhang Y; Yue W; Liu Z; Wang X; Gao S; Pan Y; Galais MP; Zaanan A; Ma Z; Li H; Wang Y; Shen L;
BMJ; 2022 Apr; 377():e068714. PubMed ID: 35440464
[TBL] [Abstract][Full Text] [Related]
53. Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial.
Kato K; Cho BC; Takahashi M; Okada M; Lin CY; Chin K; Kadowaki S; Ahn MJ; Hamamoto Y; Doki Y; Yen CC; Kubota Y; Kim SB; Hsu CH; Holtved E; Xynos I; Kodani M; Kitagawa Y
Lancet Oncol; 2019 Nov; 20(11):1506-1517. PubMed ID: 31582355
[TBL] [Abstract][Full Text] [Related]
54. Salvage treatment with irinotecan/cisplatin versus pemetrexed/cisplatin in patients with non-small cell lung cancer pre-treated with a non-platinum-based regimen in the first-line setting: a randomized phase II study of the Hellenic Oncology Research Group (HORG).
Kentepozidis N; Economopoulou P; Christofyllakis C; Chelis L; Polyzos A; Vardakis N; Koinis F; Vamvakas L; Katsaounis P; Kalbakis K; Nikolaou C; Georgoulias V; Kotsakis A
Clin Transl Oncol; 2017 Mar; 19(3):317-325. PubMed ID: 27492015
[TBL] [Abstract][Full Text] [Related]
55. Comparison of cisplatinum/paclitaxel with cisplatinum/5-fluorouracil as first-line therapy for nonsurgical locally advanced esophageal squamous cell carcinoma patients.
Hu G; Wang Z; Wang Y; Zhang Q; Tang N; Guo J; Liu L; Han X
Drug Des Devel Ther; 2016; 10():2129-36. PubMed ID: 27445460
[TBL] [Abstract][Full Text] [Related]
56. Neoadjuvant camrelizumab plus chemotherapy in treating locally advanced esophageal squamous cell carcinoma patients: a pilot study.
Yang P; Zhou X; Yang X; Wang Y; Sun T; Feng S; Ma X
World J Surg Oncol; 2021 Nov; 19(1):333. PubMed ID: 34809658
[TBL] [Abstract][Full Text] [Related]
57. [Clinical evaluation of DLF, CLF and DFM regimens based on platinum compound plus 5-fluorouracil for treatment of advanced esophageal carcinoma].
Jiang Y; Qiu XH; Yang YX; Zhang SQ; Chen ZM
Ai Zheng; 2006 Aug; 25(8):1029-34. PubMed ID: 16965688
[TBL] [Abstract][Full Text] [Related]
58. A prospective, multicenter phase I/II study of induction chemotherapy with docetaxel, cisplatin and fluorouracil (DCF) followed by chemoradiotherapy in patients with unresectable locally advanced esophageal carcinoma.
Satake H; Tahara M; Mochizuki S; Kato K; Hara H; Yokota T; Kiyota N; Kii T; Chin K; Zenda S; Kojima T; Bando H; Yamazaki T; Iwasa S; Honma Y; Hamauchi S; Tsushima T; Ohtsu A
Cancer Chemother Pharmacol; 2016 Jul; 78(1):91-9. PubMed ID: 27193097
[TBL] [Abstract][Full Text] [Related]
59. Exploratory analysis of front-line therapies in REVEL: a randomised phase 3 study of ramucirumab plus docetaxel versus docetaxel for the treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy.
Garon EB; Scagliotti GV; Gautschi O; Reck M; Thomas M; Iglesias Docampo L; Kalofonos H; Kim JH; Gans S; Brustugun OT; Orlov SV; Cuyun Carter G; Zimmermann AH; Oton AB; Alexandris E; Lee P; Wolff K; Stefaniak VJ; Socinski MA; Pérol M
ESMO Open; 2020 Jan; 5(1):. PubMed ID: 31958290
[TBL] [Abstract][Full Text] [Related]
60. A retrospective study of second-line chemotherapy for unresectable or recurrent squamous cell carcinoma of the esophagus refractory to chemotherapy with 5-fluorouracil plus platinum.
Yamazaki K; Hironaka S; Boku N; Yasui H; Fukutomi A; Yoshino T; Onozawa Y; Hasuike N; Inui T; Yamaguchi Y; Ono H
Int J Clin Oncol; 2008 Apr; 13(2):150-5. PubMed ID: 18463960
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]